Multiple sclerosis treatment more effective with older rheumatoid arthritis, lymphoma drug

Free testing for hepatitis C stepped up
May 18, 2016
Crohn’s disease linked to dietary fat, specific fatty acids may worsen disease
May 19, 2016
Show all

Multiple sclerosis treatment more effective with older rheumatoid arthritis, lymphoma drug

An older rheumatoid arthritis and lymphoma medication appears to offer some benefit for multiple sclerosis.

Multiple sclerosis (MS) treatment is more effective with older rheumatoid arthritis and lymphoma drug, according to a new study. The drug is known as Mabthera, and it has been found to be more effective in treating multiple sclerosis than many intended MS drugs. Many current multiple sclerosis drugs have adverse side effects with limit their application.

The findings come from a Swedish study where 256 patients who were previously on a well-known MS drug Tysabri switched to either Gilenya or Mabthera. Principal investigator Fredrik Piehl said, “We found that patients treated with Mabthera ran a much lower risk of their MS flaring up after the change of drugs than those treated with Gilenya. Those who changed to Mabthera also had a lower risk of developing an adverse reaction to the new drug.”

Mabthera is an older drug used to treat rheumatoid arthritis and lymphoma, and although it hasn’t been formally approved for MS treatment many patients have switched to it and have shown successful outcomes. Professor Piehl added, “The results we’ve seen in this study provide strong support for the genuine efficacy of Mabthera in the treatment of high-inflammatory MS and for it being a valuable alternative to approved MS drugs for this category of patients. It would also bring considerable savings to the healthcare services as it is much cheaper than the regular MS drugs.”

Read Full Article: Multiple sclerosis treatment more effective with older rheumatoid arthritis, lymphoma drug: New study

Read Full Article: Multiple sclerosis treatment more effective with older rheumatoid arthritis, lymphoma drug: New study

The health and medical information on our website is not intended to take the place of advice or treatment from health care professionals. It is also not intended to substitute for the users’ relationships with their own health care/pharmaceutical providers.

Comments are closed.